Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel docetaxel or vinflunine in recurrent advanced urothelial cancer: results of 2 years of follow-up

摘要

BackgroundNovel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy. Here we report the long-term safety and efficacy outcomes of KEYNOTE-045.